Advertisement

Drugs in R & D

, Volume 4, Issue 3, pp 204–206 | Cite as

Oxymorphone — Endo/Penwest

EN 3202, EN 3203
Adis R&D Profile

Keywords

Oxycodone Average Daily Dose Oxymorphone Parallel Group Study OxyContin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Endo Pharmaceuticals Inc. FDA Accepts New Drug Application for Oxymorphone Extended Release And Immediate Release Formulations. Media Release: 19 Feb 2003. Available from URL: http://www.endo.com Google Scholar
  2. 2.
    Endo Pharmaceuticals Inc. Data from Studies Investigating Extended-Release Oxymorphone Presented Today at 10th World Congress on Pain. Media Release: 21 Aug 2002. Available from URL: http://www.endo.com Google Scholar
  3. 3.
    Endo Pharmaceuticals. Clinical Trial of New Opioid Product Shows Pain Reduction in Chronic Low Back Pain. Media Release: 20 Mar 2003. Available from URL: http://www.endo.com Google Scholar
  4. 4.
    Slatkin N, Frailey A, Ma T, et al. Oxymorphone extendedrelease offers long-term safety, effectiveness, and dose stabilization in cancer pain: results of a one-year interim report. Journal of Pain 4 (Suppl. 1): 84, Mar 2003Google Scholar
  5. 5.
    Kivitz A, Ma C, Ahdieh H. Oxymorphone extended-release improves pain and quality of life in patients with osteoarthritis: results of a randomized, double-blind, placebo-controlled, dose-ranging study. Journal of Pain 4 (Suppl. 1): 80, Mar 2003Google Scholar

Copyright information

© Adis Data Information BV 2003

Personalised recommendations